SEEK announces successful Phase II challenge study of its Universal Influenza Vaccine, FLU-v

Single vaccination effective against all influenza strains

09-Nov-2011 - United Kingdom

SEEK announced encouraging results following the successful completion of its Universal Flu Vaccine Phase II challenge study. The full data was presented at the influenza Congress 2011 in Arlington, Virginia, USA.

FLU-v is the first of a new class of breakthrough T cell vaccines that are anticipated to be effective against the highly-mutagenic influenza virus. It has been developed to provide a single vaccination which is effective against all strains of influenza virus, including pandemic strains.

The trial was a challenge study whereby healthy volunteers are exposed to an attenuated (mild) strain of flu. Vaccinated subjects showed significantly lower symptom scores and viral titre levels compared with non-vaccinated subjects. In addition and most critically, blood cells from vaccinated subjects showed a cross-reactive immunity to a range of influenza viruses including both animal and human A and B strains. This demonstrates a significant breadth of response and thus the potential for a universal vaccine able to protect people against both annual flu and pandemic strains. Flu-v was well tolerated.

Gregory Stoloff, Chief Executive Officer, commented: “These data, coming so soon after the excellent Phase Ib/II HIV trial results obtained using the same technology platform, validates SEEK’s approach and methodology used in selecting its vaccine components, and demonstrates that effective and well tolerated vaccines can be produced against highly-mutating viruses.”

https://www.bionity.com/en/news/135126/seek-announces-successful-phase-ii-challenge-study-of-its-universal-influenza-vaccine-flu-v.html